In­no­va­tion En­deav­ors’ Joel Dud­ley on grow­ing in­ter­est in life sci­ences with new fund — and why he hates ‘tech­bio’

Co-found­ed by for­mer Google CEO Er­ic Schmidt, tech ven­ture cap­i­tal firm In­no­va­tion En­deav­ors an­nounced a new $630 mil­lion fund Thurs­day — but “ex­pect life sci­ences and health­care to rep­re­sent a ma­jor por­tion of the fund,” part­ner Joel Dud­ley told End­points News.

An in­vestor in Uber and SoFi, In­no­va­tion En­deav­ors has been in­creas­ing­ly in­volved in the biotech space over the past few years. It has put mon­ey in­to com­pa­nies like Eikon Ther­a­peu­tics and Zymer­gen — which was bought by Gink­go Bioworks in 2022 fol­low­ing a ma­jor im­plo­sion — and more re­cent­ly, Think Bio­science and Bi­oLoomics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER